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Abstract
Background: Deleted in liver cancer 1 (DLC1) serves as an important RhoGTPase activating protein (RhoGAP) protein that
terminates active RhoA signaling in human cancers. Increasing evidence has demonstrated that the tumor suppressive
activity of DLC1 depends not only on RhoGAP activity, but also relies on proper focal adhesion localization through its
interaction with tensin family proteins. Recently, there are reports showing that DLC1 can also be found in the nucleus;
however, the existence and the relative tumor suppressive activity of nuclear DLC1 have never been clearly addressed.
Methodology and Principal Findings: We herein provide new evidence that DLC1 protein, which predominantly associated
with focal adhesions and localized in cytosol, dynamically shuttled between cytoplasm and nucleus. Treatment of cells with
nuclear export blocker, Leptomycin B (LMB), retained DLC1 in the nucleus. To understand the nuclear entry of DLC1, we
identified amino acids 600–700 of DLC1 as a novel region that is important for its nuclear localization. The tumor
suppressive activity of nuclear DLC1 was directly assessed by employing a nuclear localization signal (NLS) fusion variant of
DLC1 (NLS-DLC1) with preferential nuclear localization. In SMMC-7721 HCC cells, expression of NLS-DLC1 failed to suppress
colony formation and actin stress fiber formation in vitro. The abrogated tumor suppressive activity of nuclear DLC1 was
demonstrated for the first time in vivo by subcutaneously injecting p53
2/2 RasV12 hepatoblasts with stable NLS-DLC1
expression in nude mice. The injected hepatoblasts with NLS-DLC1 expression effectively formed tumors when compared
with the non-nuclear targeted DLC1.
Conclusions/Significance: Our study identified a novel region responsible for the nuclear entry of DLC1 and demonstrated
the functional difference of DLC1 in different cellular compartments both in vitro and in vivo.
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Introduction
Deleted in Liver Cancer 1 (DLC1) was first cloned by
subtractive hybridization as a gene fragment that was frequently
deleted in human hepatocellular carcinoma (HCC) [1]. Accumu-
lating evidence in the last decade has supported that DLC1 is
underexpressed in various kinds of human cancers besides HCC
[2,3,4,5,6,7]. Restoration of DLC1 by ectopic expression in cells
with low or no endogenous expression of DLC1 retards cell
proliferation, induces apoptosis, slows down cell movement and
disintegrates actin cytoskeletal structure in vitro [8,9,10]. Con-
versely, DLC1 knockdown promotes tumorigenesis of a Myc
driven in vivo mouse hepatocarcinogenesis model with a p53 null
background [11]. The nature of the frequent pathological
underexpression of DLC1 and the robust experimental tumor
suppressive activity both strongly support DLC1 functions as a
bona fide tumor suppressor.
The tumor suppressive activity of DLC1 is tightly linked to its
intrinsic RhoGAP activity, which down-regulates the Rho-
mediated biological response. DLC1 has been found to be
RhoA-, B-, C- and CDC42-specific [12,13]. Focal adhesion
localization through interaction with tensin family protein is one of
the characteristics of DLC1 and is functionally associated with its
tumor suppressive activity. This was supported by the evidence
that DLC1 mutant with intact RhoGAP domain but failed to be
targeted to the focal adhesions exhibited reduced growth
suppressive activity in vitro [10,14]. Since the focal adhesion
targeting sites in DLC1 overlap with the tensin protein binding
site, it has been accepted that DLC1 couples with tensin and
functions as tumor suppressive complex in terminating the focal
adhesion-associated Rho activity [10,14,15].
A recent study has suggested the presence of basic residues rich
motif in DLC1 resembling the NLS [16]. Also, it has been
suggested that the serine/threonine specific protein kinase D
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formation with 14-3-3 sequesters DLC1 in the cytoplasm and stops
its nuclear entry [17]. However, the existence and regulation of the
nuclear DLC1 have not been thoroughly explored. Most
importantly, the relative tumor suppressive activity of nuclear
DLC1 has never been directly addressed. In this study, we have
provided comprehensive evidence that DLC1 protein constantly
shuttles between the cytoplasm and nucleus. We have performed
the first functional characterization of nuclear targeted DLC1 to
examine its basic and tumor suppressive activity both in vitro and in
vivo. By studying the subcellular localization of various DLC1
mutants, we have identified a novel region within the RhoGAP
domain which is important and sufficient for this nuclear import.
Results
DLC1 shuttled between cytoplasm and nucleus
Expression of Myc-tagged DLC1 (Myc-DLC1) in SMMC-7721
cells revealed its existence in focal adhesions, cytoplasm and
nucleus (Fig. 1A). Quantitative examination of DLC1 expression
in cells showed its dominant cytoplasmic localization with punctate
focal adhesion pattern at the cell periphery. To explore the
movement of DLC1 between the cytoplasm and nucleus, Myc-
DLC1 localization in cells was studied in cells treated with
exportin blocker, LMB. Treatment with LMB resulted in the
nuclear retention of Myc-DLC1 in SMMC-7721 and BEL7402
cells (Fig. 1B, left panel). Notably, focal adhesion localized
DLC1 was still observed, implicating only the non-focal adhesion
localized DLC1 was shuttled and retained in the nucleus. Cellular
fractionation further corroborated the presence of DLC1 in the
nuclear fraction of cell lysate (Fig. 1B, right panel). Similar
observation was obtained with GFP-tagged DLC1 (GFP-DLC1)
(data not shown). The dynamic movement of DLC1 was observed
under the withdrawal of LMB at different time points (Fig. 1C).
Re-patterning of cytoplasmic and focal adhesion was occurred
within 24 hours. We extended our investigation by examining the
localization of endogenous DLC1 in various cell lines. Subcellular
fractionation of Hep3B, HLE and SK-Hep1 cells followed by
immunoblotting using DLC1-specific antibody supports the
presence of DLC1 in the nucleus (Fig. 1D). Immunofluorescence
for endogenous DLC1 in SK-Hep1 cells showed similar
subcellular localization in the cytoplasm and nucleus (Fig. 1E).
Consistently, endogenous DLC1 in Hep3B was retained in the
nucleus after LMB treatment (Fig. 1F). To support the notion that
DLC1 shuttles between cytoplasm and nucleus under physiological
condition, we performed immunohistochemistry against DLC1 on
a human non-neoplastic liver (Fig. 1G). Positive DLC1 staining
was detected in both cytoplasm and nucleus, further supporting
that DLC1 is present in the nucleus.
DLC1 600–700 residues cooperated with NLS in the
regulation of DLC1 nuclear entry
Proteins of large molecular size possess nuclear transport signals
for active transport across the nuclear envelope with the aid of
nuclear transport complex. It has been proposed that a
monopartite NLS (423–431) [17] and bipartite NLS (415–431)
[16] are present in DLC1 which facilitate the nuclear entry of
DLC1. To specifically address the localization of DLC1 without
the proposed NLS upon LMB treatment, we constructed
DLC1D415–431 mutant specifically lacking the proposed NLS
(Fig. S1A and S1B). Expression of DLC1D415–431 in SMMC-
7721 cells showed the same subcellular localization as wildtype
DLC1. Surprisingly, DLC1D415–431 was still sensitive to LMB
treatment and was retained in the nucleus as effectively as wildtype
DLC1 (Fig. S1C). It has also been reported that phosphorylation
at serine-431 (S431) of DLC1 by protein kinase D (PKD) [17]
facilitates binding between DLC1 and 14-3-3 proteins, thus
preventing nuclear entry of DLC1. However, we found that DLC1
S431 phospho-defective mutant, S431A showed similar degree of
nuclear retention after LMB treatment (Fig. S1D). Taken
together, we could not provide sufficient evidence in supporting
the functionality of the proposed NLS as well as the role of S431
phosphorylation in regulating the nuclear transport of DLC1.
We questioned whether, apart from the nuclear targeting motif
suggested by the others, additional region in DLC1 is involved in
the nuclear localization of DLC1. To address this, we cloned and
expressed GFP-DLC1 deletion mutants and examined their
localization after LMB treatment in HeLa cells (Fig. 2A). We
found that DLC1 D292–646 internal deletion mutant showed a
significant reduction of nuclear localization upon LMB treatment
(Fig. 2B and 2C). On the other hand, nuclear retention of DLC1
1–807 C-terminal deletion mutant was not affected when
compared with wildtype DLC1 upon LMB treatment. Interest-
ingly, 1–807 mutant which contained the proposed focal adhesion
targeting region (region 200–500) [18] could not be efficiently
targeted to focal adhesions and diffusely expressed in the
cytoplasm.
It has been proposed that the N-terminal region of DLC1
negatively regulates its nuclear entry [16]. A number of potential
nuclear export signal (NES) has been mapped at 62–71, 764–773
and 792–801 residues of DLC1 by in silico search (Fig. S2A). The
importance of these signal sequences in regulating the cytoplasmic
localization was then assessed by immunofluorescence. The
functionality of NES at 764–773 and 792–801 residues were
excluded by the cytoplasmic expression of 1–291 and 1–400
mutants (Fig. S2B). Since 609-stop and 648–839 mutants
displayed enhanced nuclear localization, the role of NES at 62–
71 residues was further analyzed by creating a DLC1 D62–71
mutant. This DLC1 mutant showed characteristic focal adhesion
localization similar to the wild-type, without showing any increase
in nuclear retention (Fig. S2B). To clarify the absence of nuclear
retention was not due to the strong focal adhesion association,
DLC1 1–807D62–71, a mutant failed to localize at focal adhesions
was expressed. However, this mutant was also found to be
predominantly localized at the cytoplasm. Taken together, we
found that removal of the predicted NES at the N-terminus of
DLC1 did not affect its nucleocytoplasmic distribution.
After highlighting the nuclear targeting region to the center
region of DLC1, we performed the first detailed localization
analysis of a panel of GFP-DLC1 mutants (Fig. 3A). Interestingly,
we found that expression of 350–807 mutant showed a
predominant nuclear localization. Similar prominent nuclear
localization was seen in Myc-DLC1 291–807 (data not shown).
Examination of 600–807 mutant revealed similar nuclear
localization, while 700–807 mutant localized in both cytoplasm
and nucleus in HeLa cells (Fig. 3B and 3C). Increased nuclear
localization of 600–807 mutant was also supported by the
strongest DLC1 expression in the nuclear fraction obtained in
the biochemical fractionation assay when compared with the other
DLC1 mutants (Fig. 3D). Taken together, we found that DLC1
region 600–700 in the RhoGAP domain was also involved in the
nuclear entry of DLC1.
To further confirm the importance of this novel region, we
deleted region 601–689 in DLC1 and assessed its localization.
Interestingly, we found a marked reduction in the nuclear
localization of DLC1D601–689 mutant after LMB treatment
(Fig. 3E and 3F). As demonstrated by the D415–431D601–689
mutant in which the previously reported NLS and our mapped site
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nuclear retention much after LMB treatment. Our results
suggested that the mapped novel site plays a significant role in
targeting DLC1 into the nucleus.
Nuclear DLC1 lost its inhibitory activity in suppressing
colony formation and actin stress fiber formation in vitro
To date, there is no study assessing the direct functional
association between nuclear localization and the biological
function of DLC1. To measure the functional capacity of nuclear
DLC1 in vitro, we created and confirmed the expression of a
nuclear targeted DLC1 (NLS-DLC1) (Fig. 4A and 4B). By
immunofluorescence, we confirmed that NLS-DLC1 was pre-
dominantly localized in the nucleus in SMMC-7721 cells. An
NLS-driven DLC1 RhoGAP mutant, NLS-K714E could also be
targeted to the nucleus as efficiently as the wildtype DLC1
(Fig. 4C). We then examined the integrity of actin stress fibers in
SMMC-7721 cells transiently transfected by these mutants. Unlike
the disassembly of the actin stress fibers in the DLC1 transfected
cells, NLS-DLC1 could only partially suppress the actin stress fiber
Figure 1. DLC1 shuttled between cytoplasm and nucleus. (A) SMMC-7721 cells were transiently transfected with Myc-tagged DLC1. DLC1 was
visualized with anti-Myc antibody followed by FITC conjugated secondary antibody. Nucleus was counterstained with DAPI. Subcellular localization
pattern of DLC1 of 241 DLC1 transfected cells was counted and categorized into group A to E as indicated. (B) SMMC-7721 and BEL7402 cells were
transiently transfected with Myc-tagged DLC1 and subjected to LMB treatment followed by immunofluorescence staining with anti-Myc antibody (left
panel). The transfected cells were fractionated into cytoplasmic and nuclear portions followed by immunoblotting against Myc for exogenous DLC1,
tubulin (cytoplasmic marker), LaminB and c-jun (nuclear marker) (right panel). (C) SMMC-7721 cells were transiently transfected with Myc-tagged
DLC1, followed by LMB treatment for 6 hours. After LMB treatment (which was designated as t=0), cells were cultured with fresh medium and were
fixed at the indicated time point. Exogenous DLC1 was visualized by anti-Myc antibody. (D) Hep3B, HLE cells and SK-Hep1 cells were fractionated into
cytoplasmic and nuclear portions followed by immunoblotting using antibodies against endogenous DLC1, tubulin, LaminB and c-jun. (E)
Endogenous DLC1 in SK-Hep1 cells was visualized by polyclonal anti-DLC1 antibody, followed by FITC-conjugated secondary antibody. To serve as a
negative control, SMMC-7721 cells without DLC1 expression was stained with the polycloncal anti-DLC1 antibody. The DLC1 antibody could only
detect signal in SMMC-7721 cells with exogenous DLC1 overexpression but not the non-transfected cells. (F) Hep3B cells were treated with LMB for
6 hours. Endogenous DLC1 was then visualized by polyclonal anti-DLC1 antibody, followed by FITC-conjugated secondary antibody. (G) A section of
human non-neoplastic liver was immunostained for DLC1 (Brown). The nuclei were counterstained by hematoxylin (Blue). Cells showing positive
nuclear DLC1 staining were indicated by the solid-headed arrows. Cell nucleus showing negative DLC1 staining was indicated by the empty-headed
arrows. Scale bar: 10 mm.
doi:10.1371/journal.pone.0025547.g001
Figure 2. Center region of DLC1 was important for its nuclear localization. (A) Schematic diagram showing the structure of wildtype DLC1
(DLC1 WT) and its deletion mutants (D292–646 and 1–807). (B) HeLa cells were transiently transfected with the GFP-tagged DLC1 expression
constructs as listed in (A), followed by LMB treatment. Focal adhesions were counterstained with anti-vinculin antibody. The subcellular localization of
DLC1 was recorded by counting at least 100 transfected cells per sample. (C) Bar graph summarizing the subcellular localization of DLC1 and its
mutants in (B) with or without the LMB treatment. The results represent a duplicate of two independent experiments. The percentages of focal
adhesion positive DLC1 in individual group were also highlighted.
doi:10.1371/journal.pone.0025547.g002
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PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25547Figure 3. DLC1 600–807 within the center region was important for its nuclear localization. (A) Schematic diagram showing the structure
of a panel of DLC1 fragments terminated at amino acid 807 and a series of DLC1 internal deletion mutants for mapping the key nuclear targeting site.
The structures of wildtype DLC1 and D292–646 were also listed for comparison. (B) HeLa cells were transiently transfected with the GFP-tagged DLC1
expression constructs indicated. Focal adhesions were counterstained with anti-vinculin antibody. The subcellular localization of DLC1 was recorded
Nuclear Localization Negatively Regulates DLC1
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DLC1 K714E displayed intact actin stress fibers. Similar pattern
was observed in cells expressing NLS-K714E further supporting
that our nuclear targeting system did not exert nonspecific effect
on actin stress fiber formation. RhoGAP activity of DLC1 has
been shown to be tightly associated with its growth suppressive
activity. We then performed colony formation assay to assess the in
vitro growth suppressive activity of NLS-DLC1 in both SMMC-
7721 and HeLa cells (data not shown). In accordance with the
effect on stress fiber formation, NLS-DLC1 showed largely
reduced growth suppressive activity when compared with DLC1
(Fig. 4E) Taking together, we found that nuclear DLC1 lost
capacity to suppress cell growth.
Nuclear DLC1 did not suppress in vivo tumorigenicity
To assess the tumor suppressive activity of nuclear DLC1 in vivo,
we performed stable retroviral expression of nuclear targeted Myc-
tagged mouse DLC1 in a p53 null mouse hepatoblasts with
constitutive RasV12 activation [11]. DLC1 was targeted to the
nucleus by inserting a tandem repeat of three monopartite NLSs
(NLS3) in front of the start codon of mouse DLC1 in the retroviral
expression construct (Fig. 5A). After selection with puromycin, the
resistant clones were expanded and over 95% resistant clones were
found to be GFP positive, confirming the high retroviral
transduction efficiency (Fig. 5B). We also confirmed the successful
nuclear targeting of mouse DLC1 by immunofluorescence staining
for NLS3-DLC1 fusion protein. We found that over 90% of the
NLS3-DLC1 transduced cells showed nuclear staining when
compared with the cytoplasmic staining in DLC1 transduced cells.
Background staining with anti-Myc antibody was barely detectable
in the vector cells (Fig. 5B). We further confirmed the expression
level DLC1 proteins by immunoblotting (Fig. 5C). To further
confirm that the property of nucleocytoplasmic shuttling was
conserved in our DLC1 overexpressing hepatoblast model, we
treated DLC1 expressing cells with LMB, followed by immuno-
fluorescence. We found that treatment with LMB could
consistently retain DLC1 in the nucleus (Fig. 5D). This
observation further supported that the nucleocytoplasmic shuttling
property was conserved in the human and mouse DLC1 orthologs.
The in vivo tumorigenicity of these stable clones was examined by
subcutaneous injection in the nude mice. Consistently, DLC1
exhibited suppression effect on tumor formation, whereas nuclear
DLC1 showed a significant reduction in suppressing tumorigenic-
ity in vivo (Fig. 5E and 5F).
It has been reported that ectopic expression of DLC1 in DLC1
negative cells could induce apoptosis [19]. To test whether NLS3-
DLC1 exhibited differential biological activity in inducing
apoptosis, we established and analyzed HEK293T cells stably
expressing nuclear DLC1 by flow cytometry for the subG1 cell
population (Fig. S3B). To avoid any possible clonal effect, two
clones from each group were picked for the analysis. We found
that DLC1 expressing cells showed an increased subG1 peak when
compared with the vector and the NLS3-DLC1 expressing cells.
DLC1 expressing cells also showed a reduced G1 but increased S
population (Fig. S3B). Plausible explanation to this could be that
DLC1 expressing cells may spend longer time in S phase once they
enter the cell cycle. These observations again demonstrated that
NLS3-DLC1 was less robust in inducing apoptosis and attenuating
cell cycle progression when compared with the wildtype DLC1.
Discussion
In silico sequence analysis has revealed a number of potential
basic amino acid rich bipartite NLSs in DLC1 [16]. The presence
of these motifs prompted us to ask whether DLC1 exists as a
nuclear protein. In this study, we demonstrated that DLC1 was a
protein continuously shuttled between cytoplasm and nucleus in
different cell lines. This observation provides a balanced
explanation for the presence of nuclear DLC1 and supports its
intrinsic cytoplasmic localization as demonstrated by different
studies [10,18,20,21,22]. It is noteworthy that upon the treatment
with LMB, focal adhesion localized DLC1 was still detectable.
This observation suggested that only non-specific, cytoplasmic
DLC1 was retained in the nucleus after the treatment. Focal
adhesion localized DLC1 was relatively static in nature. This
observation is compatible to the partial nuclear staining observed
for the DLC1 focal adhesion localization defective mutant, Y442F
in a lung cell model [10]. Although positive nuclear staining could
be found in normal non-neoplastic liver in immunohistochemical
staining, it would be interesting to observe whether there is a
distinguishable difference of nuclear DLC1 staining between the
normal liver tissue and DLC1-positive HCCs (or other cancer
types).
Although the presence of nuclear DLC1 has been previously
discussed, its tumor suppressive activity in the nucleus has not been
clearly addressed. To directly investigate the tumor suppressive
activity of the nuclear DLC1, we transiently or stably expressed
NLS-DLC1 in HCC cell lines followed by a series of functional
characterization. We used this approach rather than studying the
DLC1 mutant lacking the mapped nuclear targeting signal (600–
700 residues were overlapped with the RhoGAP domain) as we
predicted that removing this signal would disrupt its intrinsic
RhoGAP activity and make the comparison with the wildtype
DLC1 impossible. Also, long term LMB treatment to produce
nuclear DLC1 is also unfavorable and it blocks global nuclear
protein export and poses stress to the cells [23]. While the novel
function of nuclear DLC1 remains to be explored, we confirmed
that NLS-DLC1 was less effective in suppressing cell growth,
disintegrating RhoA-mediated actin stress fiber formation, and
inducing cell death in vitro. NLS-DLC1 was also less effective in
suppressing tumor growth in a mouse xenograft model. We
speculate nuclear mislocalization may be a potential mechanism in
abrogating DLC1 activity in human cancer with intact DLC1
expression.
Functionally, our findings are inconsistent with the conclusion
made by previous reports. Yuan et al. demonstrated nuclear
translocation of DLC1 can induce apoptosis and facilitate its
tumor suppressive function in a transiently expressed DLC1
negative human non-small cell lung cancer (NSCLC) cell line
model [16]. However, our stable nuclear DLC1 expression model
by counting at least 100 transfected cells per sample. (C) Bar graph summarizes the percentage of cells with cytoplasmic and nuclear localization of
DLC1 and its mutants in (B). The results represent a duplicate of two independent experiments. (D) HeLa cells were transiently transfected with the
indicated GFP-tagged DLC1 expression constructs followed by subcellular fractionation. The fractionated cytoplasmic and nuclear lysates were
subjected to immunoblotting with antibodies against GFP, tubulin (cytoplasmic marker) and c-jun (nuclear marker). (E) HeLa cells were transiently
transfected with the indicated GFP-tagged DLC1 expression constructs, followed by LMB treatment. (E) Bar graph summarizes the percentage of cells
with cytoplasmic and nuclear localization of DLC1 and its mutants in (D). The results represent a duplicate of two independent experiments. Scale bar:
10 mm.
doi:10.1371/journal.pone.0025547.g003
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25547Figure 4. Transiently expressed nuclear-targeted DLC1 exhibited reduced activity in suppressing actin fiber formation and colony
formation. (A) Schematic diagram showing the structure of the nuclear targeted DLC1 (NLS-DLC1) used for transient expression experiment. The
DNA sequence encoding the monopartite NLS which consists of five basic amino acids KKKRK were inserted in front of the open reading frame of
Myc-tagged DLC1. Translation of the manipulated expression construct encoded Myc-tagged NLS-DLC1. (B) HEK293T lysates with overexpressed
Myc-tagged DLC1 or NLS-DLC1 were immunoblotted with anti-Myc antibody. (C) SMMC-7721 cells were transiently transfected with the indicated
Nuclear Localization Negatively Regulates DLC1
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in enhancing nor inducing apoptotic sub-population as indicated
by flow cytometry analysis. Plausible explanation includes
transient expression produces a very high level of DLC1 that
may cause toxicity to the cells; while our stable cell system may
have undergone some kind of adaptation during the stable cell
selection, which allows the cells to be propagated with the
expression of nuclear DLC1. Also, the cell type and cell line
dependent effects in contributing to the difference in DLC1
activity of inducing apoptosis and growth arrest have to be
considered [11,16,24]. On the other hand, Scholz et al has shown
that DLC1 S327AS431A mutant is unable to complex with 14-3-3
in the cytoplasm and is biologically more active than wildtype
DLC1. Unfortunately, the authors found that introduction of
negatively charged residues at the aforementioned sites cannot
mimic the constitutively active 14-3-3 binding conformation. The
lack of a favorable mutant hinders the assessment on how these 14-
3-3 binding residues affect the LMB sensitivity of DLC1 [17]. By
assuming the DLC1 S327AS431A is less likely to be sequestered in
the cytoplasm, one may predict that this mutant can be shuttled
into the nucleus more often. However, it is currently unknown
whether the hyperactivity of this mutant is a result of the increased
nuclear entry in short term or is due to the conformational change
that favors DLC1 RhoGAP function. It is possible that the
increased nuclear entry of a biological hyperactive DLC1 may
serve as a negative regulatory mechanism to downregulate the
hyperactive DLC1 in a long term.
Two independent studies have attempted to map the NLS in
DLC1 [16,17]. Yuan et al suggested the DLC1 415–431 is the
putative NLS, while Scholz et al suggested that DLC1 nuclear
transport requires only the latter half of the same site involving the
residues 428 and 429. However, we found that DLC1 mutant
lacking the whole proposed NLS could still be effectively retained
in the nucleus, indicating extra structural sequence in DLC1 may
be involved in this nuclear transport. To address this, we
performed detailed subcellular localization examination of GFP-
DLC1 deletion mutants. We found that DLC1 D292–646 mutant
was less LMB sensitive. Consistently, we found that expression of
fragments representing only the center region of DLC1 showed
nuclear localization. The observation implies that alteration at
both ends of DLC1 may expose elements which are driving
nuclear localization of DLC1. From these data, we further propose
and confirm that the region 600–700 in the RhoGAP domain is
important in directing nuclear localization of DLC1. LMB is a
global nuclear export blocker which, non-specifically blocks
numerous protein export besides DLC1. It remains to be tested
whether the mapped site is functionally independently; or is
capable to interact with other biomolecules in regulating the
nuclear import of DLC1. It has been suggested that the SH3
domain of p120RasGAP interacts with the DLC1 RhoGAP
domain and in turn inactivates its activity [25]. Also, the
phospholipid PIP3 has also been proposed to be required for the
optimal activity of DLC1 through the interaction of the polybasic
region resides in the RhoGAP domain [26]. Further investigation
of the involvement of other proteins and lipids by using DLC1
mutants with key interacting residues being mutated as well as cell
model with well defined genetic background is definitely useful to
answer the mechanistic regulation regarding DLC1 nuclear entry.
In addition, in an attempt to map the potential NES at 62–71
residues of DLC1, we could not observe a significant change in the
localization of DLC1 mutant without this potential NES.
There are some issues regarding the nuclear DLC1 that remain
to be resolved. It is important to determine the extracellular
stimulus and the intracellular signaling pathways guiding the
nucleocytoplasmic shuttling of DLC1. Currently, DLC1 had been
suggested to be a potential substrate of Akt, p70S6-kinase [27] and
protein kinase D (PKD) [17] pathways. Our group has recently
shown that Akt phosphorylates DLC1 at S567 residue and
inactivates its tumor suppressive activity through a RhoGAP
independent mechanism [28]. However, this particular Akt
phosphorylation did not seem to alter focal adhesion localization
and nucleocytoplasmic shuttling activity of DLC1. (unpublished
observations). Scholz et al suggests that PKD-mediated DLC1
phosphorylation at S327 and S431 residues can facilitate DLC1-
14-3-3 interaction, followed by masking the potential NLS and
sequestrating DLC1 in the cytosol in breast cancer cells [17].
However, we could not observe significant difference in terms of
the efficiency of nuclear entry among the wildtype DLC1, S431A
and S431D in LMB-treated SMMC-7721 cells (unpublished
observations).
Besides acting as a potential reservoir in the spatial regulation of
the tumor suppressive activity of DLC1, it is tempting to
investigate the nuclear functions of DLC1. It is known that
DLC1 inactivates Rho and interacts with tensin proteins at focal
adhesions in the cytoplasm; however, it is not known whether
DLC1 will interact with a nuclear specific subset of substrates or
coupled with its known cytoplasmic substrate into the nucleus.
Recently, Dubash et al further demonstrates nuclear Net1 can
activate nuclear fraction of RhoA in responding to ionizing
radiation induced DNA damage response in a HEK293 cell
model. Their findings further indicate that spatial distribution of
Rho signaling regulators may pose an extra layer of complexity to
the RhoA signaling network in responding to different biological
stimuli [29]. Follow up study to explore the novel function of
nuclear DLC1 will definitely provide new insight about the
functions as well as the general understanding about the biological
regulation of RhoGTPase signaling.
Materials and Methods
Ethics statement
The use of animal model in this study was approved by the
Committee on the Use of Live Animals in Teaching and Research
(CULATR), The University of Hong Kong. All the protocols were
strictly performed under the approved research protocol (CU-
LATR 1977-09) and the Animals (Control of Experiments)
Ordinance (Hong Kong).
wildtype DLC1 or the RhoGAP mutant (K714E) constructs. The Myc-tagged protein was visualized by anti-Myc antibody followed by FITC-conjugated
secondary antibody. The subcellular localization of DLC1 was recorded by counting at least 100 transfected cells per each sample. Bar graph indicates
the percentage of cells with nuclear DLC1 staining. The results represent a duplicate of two independent experiments. (D) SMMC-7721 cells were
transiently transfected with the indicated Myc-tagged DLC1 constructs and the actin stress fibers were stained with TRITC-conjugated phalloidin
1 hour after the serum induction. The asterisk (*) marks the DLC1-transfected cells. (E) Bar graph showing the relative colony formation efficiency of
SMMC-7721 cells being transfected with the indicated DLC1 constructs and pEGFP-C1 vector carrying neomycin resistant gene in 10:1 ratio. The
transfected cells were selected with G418 for 2 weeks. The colonies formed were visualized by crystal violet staining and quantified. The mean
difference between the indicated group was found to be statistically significant (***P,0.005; unpaired t-test). Scale bar: 10 mm.
doi:10.1371/journal.pone.0025547.g004
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2/2 hepatoblasts with stable nuclear targeted DLC1 expression exhibited reduced tumor suppressive
activity in vivo. (A) Schematic diagram illustrating the retroviral vectors used to drive the stable expression of Myc-tagged mouse DLC1 and the
nuclear-targeted mouse DLC1 (NLS3-DLC1). (B) Hepatoblasts infected with vector, DLC1 or NLS3-DLC1 retroviruses were fixed and the expression of
Myc-tagged protein was visualized by anti-Myc antibody followed by Texas Red-conjugated secondary antibody. (C) Lysates of infected hepatoblasts
with vector, DLC1 or NLS3-DLC1 retroviruses were subjected to immunoblotting using antibodies against Myc, DLC1 and GFP. b-actin was served as
the loading control. (D) Hepatoblasts infected with DLC1 retrovirus were subjected to LMB treatment. The cells were then fixed and the localization
of the Myc-tagged DLC1 was visualized by anti-Myc antibody followed by Texas Red-conjugated secondary antibody. Bar graph indicates the
percentage of cells with nuclear DLC1 staining. The results represent a duplicate of two independent experiments. (E) The tumorigenicity of the
indicated retroviral transduced hepatoblasts was assessed by subcutaneous nude mice injection. 1610
5 hepatoblasts were subcutaneously injected
at day 0 and the volume of the tumor size was monitored daily from day 4. All mice were sacrificed at day 14. At day 14, the mice were sacrificed and
the tumors were dissected. (F) The dissected tumors were weighed and their masses were recorded. Scale bar: 10 mm.
doi:10.1371/journal.pone.0025547.g005
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Human hepatoma cell lines, HepG2, Hep3B and SK-Hep1;
human cervical carcinoma cell line HeLa and human embryonic
kidney cell line HEK293T were obtained from American Type
Culture Collection (Manassas, VA, USA), whereas the human
HCC cell lines, SMMC-7721 and BEL7402 were obtained from
the Shanghai Institute of Cell Biology. Mouse p53
2/2; RasV12
hepatoblastoma cell line was a generous gift from Dr. Scott W.
Lowe of Cold Spring Harbor Laboratory, USA. HepG2,
HEK293T, HeLa, SMMC-7721, BEL7402 and p53
2/2; RasV12
cells were maintained in DMEM high glucose medium supple-
mented with 10% (v/v) fetal bovine serum, penicillin and
streptomycin. SK-Hep1 and Hep3B cells were maintained in
MEM medium supplemented with 10% (v/v) fetal bovine serum,
penicillin and streptomycin. All cells were cultured in a humidified
incubator at 37uC with 5% CO2 in air. Transfection with the
indicated plasmid was done with Lipofectamine 2000 reagent,
according to the manufacturer’s instructions (Invitrogen, Carlsbad,
CA, USA).
Plasmids
DNA expression constructs using pCS2+MT, pEGFP-C1 (BD
Biosciences Clontech, Palo Alto, CA, USA) and pMSCV-6X-Myc-
Puro-IRES-GFP (gift from S. W. Lowe) vectors were prepared by
standard molecular cloning techniques and PCR amplification of
the described fragments. Eukaryotic expression vectors for Myc-
tagged proteins were derived from pCS2+MT and prepared as
follows: DLC1 1–1091 (WT, wildtype), K714E (RhoGAP mutant)
and D415–431. NLS-DLC1 and NLS K714E were prepared by
subcloning the DLC1 WT and K714E cDNAs into the pCS2+MT
derived pCS2+MT+NLS vector. In brief, a pair of complementary
oligonucleotides 59-GATCCGCCGCCATGGCTCCAAAGAA-
GAAGCGTAA GGTAAAT-39 and 59-CGATTTACCTTAC-
GCTTCTTCTTTGGAGCCATGGCGGCG-39 was reannealed,
double digested with BamHI and ClaI, followed by subcloning into
the multiple cloning sites of the pCS2+MT vector. Eukaryotic
expression vectors for GFP-tagged proteins were derived from
pEGFP-C1 and prepared as follows: DLC1 WT, D292–646, D62–
71, D415–431, D601–689, D415–431D601–689, 1–291, 1–400, 1–
807, 1–807 D62–71, 350–807, 600–807, 700–807, 609-stop, 648–
839. Retroviral expression vectors for Myc-tagged proteins were
derived from pMSCV-6X-Myc-Puro-IRES-GFP and prepared as
follows: mouse DLC1 WT (gift from S. Lowe). Mouse NLS-DLC1
was prepared by first ligating BamHI cut cDNA of a tandem repeat
of three basic, monopartite NLSs in front of the multiple cloning site
of the retroviral expression vector, followed by the subcloning of the
mouse DLC1 cDNA in frame behind the 39 region of the inserted
NLSs. All DNA expression constructs were confirmed by DNA
sequencing.
Immunofluorescence microscopy and LMB treatment
For the subcellular localization studies, cells were fixed with 4%
paraformaldehyde in PBS for 15 minutes and then permeabilized
with 0.2% Triton-X-100 in PBS for 10 minutes, followed by
blocking with 3% bovine serum albumin in PBS for 20 minutes at
room temperature. The blocked coverslips were then incubated
with the primary antibody, followed by FITC- or Texas Red-
conjugated secondary antibody, for 1 hour each. Myc-tagged
protein was stained with monoclonal anti-Myc antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Endogenous DLC1
was stained with polyclonal anti-DLC1 antibody (Santa Cruz
Biotechnology). The endogenous vinculin was stained by mono-
clonal anti-vinculin (Sigma, St. Louis, MO, USA) antibody. The
F-actin was visualized by tetramethylrhodamine B isothiocyanate
(TRITC)-labeled phalloidin (Sigma) one hour after serum
induction. The processed coverslips were mounted in Vectashield
anti-fade mounting medium (Vector Laboratories, Burlingame,
CA, USA). Images were captured by a Leica Q550CW
fluorescence microscope (Leica, Wetzler, Germany).
For the LMB (Sigma) treatment, a protocol of 10 ng/ml LMB
for 6 hours was employed, unless stated otherwise in specific
experiment. To study the effect of LMB on transiently expressed
protein, cells were transfected with the indicated DLC1 construct
for 16 hours before the treatment. For the study concerning the
endogenous DLC1, LMB treatment was employed 24 hours after
seeding cells on the coverslips.
Subcellular fractionation
To harvest cells for fractionation, 2610
6 cells were washed once
with PBS and harvested by trypsinization followed by centrifuga-
tion at 15006g for 5 minutes. The cell pellet was further washed
with 10 ml PBS and was then transferred to a microcentrifuge
tube. Cell pellet was collected by centrifugation at full speed for
15 seconds. To perform cell lysis and extract the cytoplasmic
fraction, cell pellet was gently resuspended in 400 ml ice-cold
buffer A (10 mM HEPES, pH7.9, 10 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM DTT and 0.5 mM PMSF) and was
incubated on ice for 15 minutes. Twenty percent NP-40 (v/v)
solution of 12.5 ml was then added to the cell suspension followed
by vigorous vortexing for 10 seconds. The homogenate was
cleared by centrifugation at full speed for 30 seconds. The
supernatant was collected as the cytoplasmic fraction. To extract
the nuclear fraction, the nuclear pellet was resuspended in 50 ml
ice-cold buffer C (20 mM HEPES, pH7.9, 400 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT and 1 mM PMSF) and was
incubated on ice for 15 minutes with vortex every 3 minutes. The
nuclear extract was collected by cold centrifugation at full speed
for 5 minutes. The supernatant contained the nuclear fraction.
Ten to twenty mg of extract from each fraction was separated on a
10% SDS-PAGE. The endogenous tubulin and c-Jun was
immunoblotted with monoclonal anti-tubulin (Sigma) and anti-c-
Jun antibodies (BD-transduction, San Jose, CA, USA) as
cytoplasmic and nuclear markers respectively.
Cell lysis and western blotting
The harvested cells were lysed with NET-N buffer (25 mM
Tris-HCl, pH 8.0, 50 mM NaCl, 0.2 mM EDTA, 0.1% NP40)
and a cocktail of protease inhibitors (Roche, Mannheim,
Germany) on ice for 20 minutes. The cell lysate was cleared by
centrifugation at 16,0006g for 15 minutes at 4uC. Ten to twenty
mg of boiled cell lysates were subjected to SDS-PAGE analysis.
The Myc-tagged and GFP-tagged proteins were immunoblotted
with monoclonal anti-Myc and anti-GFP antibodies (Santa Cruz
Biotechnology). The endogenous DLC1 was immunoblotted with
polyclonal anti-DLC1 antibody (Santa Cruz Biotechnology).
Endogenous tubulin or b-actin was detected by monoclonal anti-
tubulin or anti-b-actin antibodies (Sigma) as a loading control.
Immunohistochemistry
Immunohistochemical staining for DLC1 was performed on
formalin-fixed, paraffin-embedded sections using the EnVision
TM
+ Kits (Dako, Glostrup, Denmark). The cut sections were first
dewaxed in xylene, rehydrated through graded ethanol. For
antibody retrieval, the sections were boiled with EDTA (1 mM,
pH=8.0) solution for 15 minutes. To block the endogenous
peroxidase activity, the sections were treated for 3% H2O2 for
30 minutes. The samples were then incubated with rabbit
polyclonal anti-DLC1 antibody for 1 hour at room temperature.
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TM+Kits (Dako)
according to the suggested protocol by the manufacturer. Nucleus
was counterstained by hematoxylin. The stained sections were
dehydrated, mounted on glass slides and observed under the
microscope.
Colony formation assay
Cells were seeded at 1610
5 cells per well on a 6-well plate were
transfected with Myc-tagged DLC1 construct and pEGFP-C1
vector carrying neomycin resistant gene in 10:1 ratio for 24 hours.
Transfected cells were then seeded with medium containing
0.5 mg/ml G418 for two weeks. The colonies formed were fixed
after selection and visualized by crystal violet staining. The
number of colonies was analyzed by AlphaEase FC Software
(Alpha Innotech Corporation).
Retroviral packaging and transduction
For transient retroviral packaging, pMSCV-Puro-IRES-GFP
based retroviral construct was transfected into PA317 packaging
cells with Lipofectamine 2000 reagent. Sixteen hours after
transfection, cells were cultured in 10 ml fresh medium to collect
the retroviral particles for 24 hours. To purify the retroviral
particles, the collected medium was transferred to a clean
centrifuge tube and the cell debris was cleared by centrifugation
at 16676g for 3 minutes at room temperature. The supernatant
was then used for subsequent viral transduction.
For stable retroviral transduction, 5610
4 p53
2/2; RasV12
hepatoblasts or HEK293T cells were seeded on a six well plate
one day before viral transduction. The cells were incubated with
1 ml viral particles supplemented with 8 mg/ml polybrene for
24 hours, followed by a recovery period of 48 hours in fresh
medium. The viral-infected hepatoblasts and HEK293T cells
were then selected with 5 mg/ml and 0.5 mg/ml puromycin
respectively for 10 days.
Subcutaneous Injection in Nude Mice
To assess the tumorigenicity of mouse DLC1 overexpressing
hepatoblasts, 1610
5 cells suspended in 100 ml PBS were injected
subcutaneously into the back of male BALB/C nude mice at 4
weeks of age. Five mice were injected per stable clone. Tumor sizes
were measured daily starting at day 4 post-injection. Mice were
sacrificed at day14 post-injection and the tumors were then
excised, weighed and photographed. Tumor volume was calcu-
lated by the formula: K6L6W
2 (L: length of tumor; W: width of
tumor). This experiment was performed according to the Animals
(Control of Experiments) Ordinance (Hong Kong) and all the
procedures were strictly followed the guidance on animal
experimentation set out by the University of Hong Kong.
Propidium iodide staining and flow cytometry
To prepare cells for propidium iodide staining, 5610
5
HEK293T cells were harvested by trypsinization and were
f i x e dw i t hi c e - c o l d8 0 %e t h a n o li nP B S .T h ef i x e dc e l l sw e r e
then treated with 50 mg/ml RNaseA for 30 minutes at 37uC
followed by DNA staining with 50 mg/ml propidium iodide for
5 minutes at room temperature. The DNA content of the cells
was then analyzed by FACSCalibur flow cytometer (BD
Biosciences).
Supporting Information
Figure S1 DLC1 DNLS (D415–431) could still be retained
in the nucleus upon LMB treatment in SMMC–7721
cells. (A) Schematic diagram showing the proposed NLS in DLC1
as stated by Yuan et al and Schloz et al. The S431 site was proposed
as a 14-3-3 docking site which modulates the DLC1 nuclear entry
by Scholz et al. The structure of DLC1 DNLS (D415–431) and
S431A mutants were outlined. (B) Western blotting showing the
protein expression of Myc-tagged wild type DLC1 and DNLS
mutant in transiently transfected SMMC-7721 cells. (C) Immuno-
fluorescence staining showing the localization of wildtype DLC1
and DNLS in the presence or absence of LMB. DLC1 was
visualized with anti-Myc antibody following by FITC conjugated
antibody. Nucleus was counterstained with DAPI. The subcellular
localization of DLC1 was recorded by counting at least 100
transfected cells per sample. Bar graph summarizing the subcellular
localization patterns of DLC1 and the DNLS mutant. The results
represent a duplicate of two independent experiments. (D)
Immunofluorescence staining showing the localization of wildtype
DLC1 and S431A mutant in cells in the presence or absence of
LMB. Bar graph summarizing the subcellular localization patterns
of DLC1 and the DNLS mutant. The results represent a triplicate of
three independent experiments. Scale bar: 10 mm.
(TIF)
Figure S2 Prediction and characterization of potential
Nuclear Exporting Signals (NES) in DLC1. (A) Schematic
diagram showing the position of the three potential NESs in DLC1
based on the in silico search for Leucine rich motif
(LXXXLXXLXX; L=Leucine; X=Any amino acids). The
structure and subcellular localization of DLC1 constructs used to
pinpoint the potential NES were listed. (B) (E) HeLa cells were
transiently transfected with GFP-tagged DLC1 expression con-
structs listed in (A). Focal adhesions were counterstained with anti-
vinculin antibody. Scale bar: 10 mm.
(TIF)
Figure S3 Stable expression of nuclear targeted DLC1
was less potent in inducing apoptotic subG1 cell
population in HEK293T cells. (A) HEK293T cells were
transduced with the indicated retroviruses. Two individual clones
of each group were picked and propagated. Transduced cells were
GFP positive. HEK293T cells transduced with the indicated
retroviruses were lysed and subjected to immunoblotting using
anti-Myc and anti-GFP antibodies. Tubulin was served as the
loading control. (B) HEK293T cells transduced with the indicated
retroviruses were subjected to flow cytometry analysis for
propidium iodide staining. The cell cycle profiles of individual
cell lines were shown.
(TIF)
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